Brought to you by 
Cytel acquires vaccine division Epimmune
02 Feb 2000
Executive Summary
After its decision to focus on immunology instead of cell adhesion, Cytel Corp. will acquire majority-owned subsidiary Epimmune Inc. (vaccines) and call itself Epimmune. Cytel, which already owns 66% of the division, will issue 2.4mm common and preferred shares to acquire the stock it doesn't own.
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cytel acquires vaccine division Epimmune
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice